🔗 Share this article

Given that the United States continues making unprecedented adjustments to its vaccination guidelines, an unexpected name has surfaced somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who first made her name by questioning coronavirus vaccinations during the pandemic and has focused upon alleged deaths following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to announce sweeping revisions to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with much of the world with little proof for benefit. The announcement has been pushed back until the next year.

Instead of the director of the vaccine center, Dr. Høeg is set to speak at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to lead the center this calendar year.

A Shift at the Regulatory Body

This interim role might represent a strengthened alliance between the drug and biologics branches as Høeg and Dr. Prasad solidify control at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting specific childhood immunization guidelines in the US in order to be more similar to the Danish model, a society with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on immunizations – traditionally the domain of Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Background

Høeg has no obvious track record in medication creation, approval processes or management, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a large organization. She is not an expert in drug approvals.”

Previous commissioners of CBER would “grasp legal statutes and the science of medication creation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that previous people who led CBER have had.”

This division has an enormous workload at the FDA, she stated.

“Many people just focuses on the new drug program, but the generic drug division authorizes a multitude of generic medications. There is also a biologic copycat branch, non-prescription drug unit and other areas, and every single one must be looked after,” she explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the role, which oversees over 5,000 personnel. “It’s a enormous leadership role, if you execute it properly,” the former official added.

Agency Reaction and Contentious Programs

In response to questions about Dr. Høeg's credentials and whether this assignment represents greater collaboration among FDA leaders on immunizations, a representative said that the “inquiries stem from flawed premises”.

“This background aligns with the responsibilities of her role,” the representative said, noting the period Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg takes over the commissioner’s new fast-track approval initiative, a disputed expedited medication authorization process that apparently concerned her former heads. “By what process are these medications being picked for this voucher program? Who is making the decisions?” Dr. Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he stated, “the agency seems to be moving towards more relaxed rules of most medications, with the exception of immunizations.”

Public Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a more documented, if troubling, past, some experts have noted. She published a study using unverified crowd-sourced reports to estimate the rate of myocarditis following COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming government encompassed revising regulations for new vaccines and ending “optional” immunizations, she said post-election on a podcast. At the agency, Dr. Høeg has reportedly proposed excluding adolescent males from getting COVID-19 vaccines.

“She’s an thorough dogmatist who begins with her beliefs and reverse-engineers to retrofit the evidence in a very deceptive, untruthful manner,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow skeptics, {like|